Articles

81. A Focus On CNS (Central Nervous System) 5/11/2011
    Today, developing differentiated drugs that deliver demonstrable patient benefits and added value is more challenging than ever.
82. Case Study: Simplifying Data Management In A Complex Study 5/11/2011
    For a Global trial, our customer worked with multiple players, including affiliates and an external CRO.
83. Data Driven Market Success 5/11/2011
    A Quintiles customer needed an experienced post-marketing ally who could plan for the unknown and design an observational study to eventually include several affiliates, thousands of sites, and more than 55,000 patients, with start-ups staggered over time.
84. Aptuit Blister Packaging Case Study 4/28/2011
    A client, in need of global blister packaging, had received an exorbitant estimate from a Clinical Packaging and Logistics provider other than Aptuit.
85. Mastering The Extended Clinical Supply Chain Whitepaper: Strategic Advantages For Clinical Trials 4/28/2011

    The core of any good clinical supply chain system is a supply management system that addresses all of the nuances of clinical supplies.

86. Integrating Clinical Supply Systems & Outsourced Service Providers Whitepaper 4/28/2011

    Pharmaceutical and biotech companies of all sizes are increasingly turning to third parties to execute some or all of their clinical supply activities.

87. Government And Industry Come Together To Stop $75B Drug Counterfeit Ring 4/15/2011

    Anticounterfeiting specialists believe that medicine counterfeiting is expected to increase this year, according to a survey by Pharma IQ. By Cindy Dubin

88. Article: Cold Chain Pharmaceuticals Worth Billions 4/13/2011
    There is a growing global demand for increasingly complex drugs and pharmaceutical products, a market that will grow to U.S. $900B by 2012 and $1.2T by 2014. By American Airlines Cargo
89. Improving Pharmaceutical Manufacturing Regulatory Risk 3/15/2011

    Pharmaceutical manufacturers must manage regulatory risk to ensure products are developed and produced in manner consistent with organizational goals and strategic objectives. Ongoing operations and marketplace supply can be hindered if a producer is not keenly aware of the regulatory environment and potential risks of underperforming processes. Operational requirements for development of clinical supply may also be adversely affected when regulatory issues exist. Similarly, drug development may be hindered by poorly performing production processes for managing laboratory testing, facilities and systems, quality and packaging/labeling. By ACSYS, Inc.

90. Comprehensive Preclinical Development Program 4/9/2010
    Aptuit was asked to conduct an extended package of preclinical studies within a short time frame. As the critical studies are dependent on the results of earlier work in the package (for example, initiation of the 28 day toxicology studies are dependent on the completion of bioanalytical method development, dose range finding, etc.) not only scheduling, but adherence to the schedule was the major risk to achievement of the overall aim, and on time filing to the regulator. By Aptuit, Inc.